CytRx receives FDA approval to continue aldoxorubicin clinical trial CytRx announced it has received approval from the FDA to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas. The clinical trial is scheduled to begin this quarter. For purposes of the clinical trial, disease progression is defined as an increase in the size of measurable tumors by 20% or the development of a new tumor lesion.
News For CYTR From The Last 14 Days
Check below for free stories on CYTR the last two weeks.